<DOC>
	<DOCNO>NCT00502541</DOCNO>
	<brief_summary>This multi-center , randomize , mask , parallel-group , control study patient diabetic macular edema , compare RetisertTM ( 0.59 mg ) control therapy ( standard care ( SOC ) - repeat macular grid laser observation ) . The objective evaluate safety efficacy intravitreal fluocinolone acetonide implant treatment patient diabetic macular edema .</brief_summary>
	<brief_title>Efficacy Fluocinolone Acetonide Intravitreal Implant Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Males nonpregnant female least 18 year age , DME study eye Edema must involve fixation least 1 disc area size Visual acuity ≥20 ≤68 letter ETDRS study eye The study eye must receive least one macular laser treatment &gt; 12 week prior entry study Ability willingness comply treatment followup Ability understand sign Informed Consent form Pregnant , lactate female Allergy fluocinolone acetonide component delivery system Any disease condition would preclude study treatment follow Presence screening IOP great equal 22 mm HG antiglaucoma medication ( ) . History uncontrolled IOP within last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>